MetaCap

Clene (CLNN) vs Citius Oncology (CTOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Citius Oncology (CTOR) has outperformed Clene (CLNN) over the past year, losing 55.4% versus a loss of 62.0%. Citius Oncology is the larger company by market cap ($53.2 million vs $50.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLNN-62.03%CTOR-55.44%
+51%-11%-72%
Nov 21, 20251 yearNov 20, 2026
CLNN-82.40%CTOR-95.01%
+321%+103%-115%
Dec 5, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLNN versus CTOR key metrics
MetricCLNNCTOR
Share price$3.52$0.5035
Market cap$50.69M$53.25M
1-day change+0.57%-10.95%
YTD return-40.03%-49.65%
1-year return-62.03%-55.44%
5-year return-96.28%—
EPS (TTM)$-2.30$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$200.00K—
Revenue growth (YoY)-41.52%—
Net income (latest FY)$-26.17M$-24.76M
Gross margin78.50%—
Operating margin-11541.50%—
Net margin-13086.50%—
52-week high$10.84$1.83
52-week low$3.02$0.491
Distance from 52-week high-67.53%-72.49%
Analyst consensusnonenone
Avg. price target upside+814.77%+694.44%
Average volume115.06K114.02K
Shares outstanding14.40M105.76M
Employees76—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Clene

CLNN stock →

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About Citius Oncology

CTOR stock →

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.

Health Care · Biotechnology: Pharmaceutical Preparations

CLNN vs CTOR FAQ

Which is bigger, Clene or Citius Oncology?

Citius Oncology (CTOR) is larger, with a market capitalization of $53.25M compared with $50.69M for Clene (CLNN).

Which stock has performed better over the past year, CLNN or CTOR?

CTOR returned -55.44% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.

Are Clene and Citius Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons